» Articles » PMID: 28393412

Early Stages in the Ontogeny of Small B-cell Lymphomas: Genetics and Microenvironment

Overview
Journal J Intern Med
Specialty General Medicine
Date 2017 Apr 11
PMID 28393412
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

In this review, we focus on the mechanisms underlying lymphomagenesis in chronic lymphocytic leukaemia, follicular lymphoma, mantle cell lymphoma and splenic marginal zone lymphoma. The cells of origin of these small B-cell lymphomas are distinct, as are the characteristic chromosomal lesions and clinical courses. One shared feature is retention of expression of surface immunoglobulin. Analysis of this critical receptor reveals the point of differentiation reached by the cell of origin. Additionally, the sequence patterns of the immunoglobulin-variable domains can indicate a role for stimulants of the B-cell receptor before, during and after malignant transformation. The pathways driven via the B-cell receptor are now being targeted by specific kinase inhibitors with exciting clinical effects. To consider routes to pathogenesis, potentially offering earlier intervention, or to identify causative factors, genetic tools are being used to track pretransformation events and the early phases in lymphomagenesis. These methods are revealing that chromosomal changes are only one of the many steps involved, and that the influence of surrounding cells, probably multiple and variable according to tissue location, is required, both to establish tumours and to maintain growth and survival. Similarly, the influence of the tumour microenvironment may protect malignant cells from eradication by treatment, and the resulting minimal residual disease will eventually give rise to relapse. The common and different features of the four lymphomas will be summarized to show how normal B lymphocytes can be subverted to generate tumours, how these tumours evolve and how their weaknesses can be attacked by targeted therapies.

Citing Articles

An Immune-Clinical Prognostic Index (ICPI) for Patients With Follicular Lymphoma Treated With R-CHOP/CHOP Chemotherapy.

Lu Y, Yu J, Gong W, Su L, Sun X, Bai O Front Oncol. 2021; 11:708784.

PMID: 34336695 PMC: 8316046. DOI: 10.3389/fonc.2021.708784.


The NOTCH Pathway and Its Mutations in Mature B Cell Malignancies.

Arruga F, Vaisitti T, Deaglio S Front Oncol. 2018; 8:550.

PMID: 30534535 PMC: 6275466. DOI: 10.3389/fonc.2018.00550.


Improved biological insight and influence on management in indolent lymphoma. Talk 3: update on nodal and splenic marginal zone lymphoma.

Thieblemont C Hematology Am Soc Hematol Educ Program. 2017; 2017(1):371-378.

PMID: 29222281 PMC: 6142593. DOI: 10.1182/asheducation-2017.1.371.